Advisornet Financial’s TG Therapeutics TGTX Stock Holding History

Advisornet Financial’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$89K	Hold	1,620	–	–	﹤0.01%	920
2026 Q1	$53.8K	Hold	1,620	–	–	﹤0.01%	1032
2025 Q4	$48.3K	Hold	1,620	–	–	﹤0.01%	1060
2025 Q3	$58.5K	Buy	+1,620	New	+$53.4K	﹤0.01%	977
2025 Q2	–	Sell	-251	Closed	-$9.9K	–	2365
2025 Q1	$9.9K	Buy	+251	New	+$8.45K	﹤0.01%	1417
2020 Q1	–	Sell	-3,000	Closed	-$33K	–	1932
2019 Q4	$33K	Sell	3,000 -1,500	-33%	-$11.4K	﹤0.01%	1027
2019 Q3	$25K	Buy	4,500 +500	+13%	+$3.49K	﹤0.01%	1130
2019 Q2	$35K	Sell	4,000 -250	-6%	-$1.89K	﹤0.01%	915
2019 Q1	$34K	Buy	4,250 +1,000	+31%	+$5.41K	﹤0.01%	847
2018 Q4	$13K	Sell	3,250 -825	-20%	-$4.1K	﹤0.01%	1026
2018 Q3	$23K	Buy	4,075 +3,775	+1,258%	+$43.1K	﹤0.01%	927
2018 Q2	$4K	Buy	+300	New	+$4.13K	﹤0.01%	1323

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Advisornet Financial's TGTX Position: Q2 2026 in Review

Advisornet Financial held its TG Therapeutics (TGTX) position steady in Q2 2026 at 1,620 shares worth $89K. The position accounts for ﹤0.01% of the portfolio, ranked #920.

Advisornet Financial first reported a position in TGTX in Q2 2018 and has held it in 12 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Advisornet Financial held 1,620 shares of TG Therapeutics worth $89K as of Q2 2026.
Advisornet Financial left its TG Therapeutics share count unchanged in Q2 2026.
TG Therapeutics made up ﹤0.01% of Advisornet Financial's portfolio in Q2 2026, its #920 holding.
Advisornet Financial first reported a position in TG Therapeutics in Q2 2018 and has held it in 12 quarters since.
431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Advisornet Financial's 13F filing for Q2 2026, filed 23 Jul 2026.